PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC2)
PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study
Sponsor: ALN Implants Company
This PHASE4 trial investigates Pulmonary Embolism and Venous Thrombosis and is currently completed. ALN Implants Company leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ALN Implants Company
- Centre Hospitalier Universitaire de Saint Etienne
- Fondation de France
- Fondation de l'Avenir
- Ministry of Health, France
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Besançon, France , Bordeaux, France , Brest, France , Clamart, France , Clermont-Ferrand, France , Dijon, France , Firminy, France , Grenoble, France and 9 more locations